Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]

Blog Article

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]Martinez-Garcia MA, Miravitlles M.Int J Chron Obstruct Pulmon Dis.2017;12:1401–1411.Page 1409, Disclosure, the text “The authors report no conflicts of interest in this work” should read “MM has 5-HTP received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharma, Verona Pharma, pH Pharma, Novartis and Grifols; Remotes and research grants fromGlaxoSmithKline and Grifols.MAM has received speaker fees from Chiesi, Grifols, Novartis, TEVA and Zambon; onsultancy fees from Zambon and TEVA; and research grants from Zambon”.

Read the original article   .